LC-MS Study Shows Reliable way to Measure Leukemia Markers
A study led by cancer researchers at Ohio State University's Comprehensive Cancer Center's Experimental Therapeutics Program.has validated a method for reliably measuring variations in certain proteins that may make good biomarkers in chronic leukemia patients.
A study led by cancer researchers at Ohio State University's Comprehensive Cancer Center's Experimental Therapeutics Program.has validated a method for reliably measuring variations in certain proteins that may make good biomarkers in chronic leukemia patients. The study shows that LC-MS can measure variations in histones. The technology accurately detected differences in the composition of histones in chronic lymphocytic leukemia (CLL) cells compared with their healthy counterparts- B lymphocytes. These variations are a promising molecular biomarker that might improve the diagnosis and gauge response to therapy in CLL patients.
Advancing Bladder Cancer Research with Mass Spectrometry: A FeMS Interview with Marta Relvas-Santos
November 12th 2024LCGC International interviewed FeMS Empowerment Award winner Marta Relvas-Santos on her use of mass spectrometry to identify potential biomarkers and therapies for bladder cancer. She also shared insights on her work with FeMS and advice for fellow scientists.
Exploring The Chemical Subspace of RPLC: A Data-driven Approach
November 11th 2024Saer Samanipour from the Van ‘t Hoff Institute for Molecular Sciences (HIMS) at the University of Amsterdam spoke to LCGC International about the benefits of a data-driven reversed-phase liquid chromatography (RPLC) approach his team developed.
